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Objective.  To evaluate, retrospectively, the roles of endoge-
nous and exogenous luteinising hormone (LH) activity on live 
birth rate in ovulation induction cycles.
Methods.  Associations  between  LH  activity  at  baseline, 
end of stimulation and live birth rate were analysed in rela-
tion to patient characteristics, baseline and end of stimula-
tion variables in WHO group II anovulatory women (n  =  155) 
stimulated  with  recombinant  follicle-stimulating  hormone 
(rFSH) or highly purified human menopausal gonadotrophin 
(HP-hMG). HP-hMG provides FSH and exogenous LH ac-
tivity mainly in the form of human chorionic gonadotrophin 
(hCG).
Results.  Serum  LH  concentrations  at  baseline  or  end  of 
stimulation were not predictive of live birth rate in the rFSH 
group (n  =  79) or HP-hMG group (n  =  76). Serum hCG con-
centration at end of stimulation was a significant positive pre-
dictor in HP-hMG-treated women. Other variables were not 
independently predictive of live birth in either of the groups, 
except for a negative association between serum FSH concen-
trations at the start of stimulation and live birth in the rFSH-
treated group.
Conclusions.  Endogenous LH concentrations are not pre-
dictive of live birth in anovulatory WHO group II patients 
undergoing  ovulation  induction  with  rFSH  or  HP-hMG. 
On  the  other  hand,  exogenous  hCG  activity  during  HP-
hMG  stimulation  is  positively  associated  with  treatment 
outcome.
Keywords:  Highly purified menotrophin, human chorionic 
gonadotrophin, infertility, live birth, luteinising hormone, 
ovulation induction
Introduction
WHO group II anovulatory infertility is the most fre-
quent anovulatory disorder, with the majority of such 
patients  being  diagnosed  with  polycystic  ovary  syn-
drome (PCOS) (van Santbrink et al., 1997; Laven et al., 
2002). Management includes first-line treatment with 
clomiphene citrate (CC), and those who fail to ovulate 
or conceive during CC treatment respond well to go-
nadotrophin treatment (Hamilton-Fairley et al., 1991; 
Balen et al., 1994; Homburg & Howles, 1999).
Despite  a  normal  follicle  stimulating  hormone 
(FSH) concentration, an elevated luteinising hormone 
(LH) concentration is not unusual in PCOS patients 
(Laven et al., 2002). Both the absolute concentration 
of circulating endogenous LH and the LH to FSH ratio 
are elevated in about 40% of these patients (Conway 
et al., 1989; Franks, 1989; Fauser et al., 1991; Balen 
et al., 1995; Taylor et al., 1997). The pathophysiology of 
the elevated LH concentration is not fully understood 
(Laven et al., 2002).
A number of studies are available on the impact of 
endogenous LH on fertility as well as treatment out-
come during stimulated cycles in anovulatory patients. 
In women with regular spontaneous menstrual cycles, 
the endogenous LH concentration has been found to be 
higher in women with primary or secondary infertility 
than in fertile women (Regan et al., 1990). The associa-
tion between elevated endogenous LH concentrations 
and miscarriage rates are inconsistent, both in women 
with normal ovarian morphology and in women with 
PCOS (Regan et al., 1990; Rai et al., 2000).
In PCOS women undergoing CC treatment, a high 
endogenous LH concentration prior to treatment has 
been associated with a high probability of conceiving 
(Kousta et al., 1997; Imani et al., 1999), whereas elevat-
ed endogenous LH concentrations during the follicular 
phase of CC treatment have been associated with poor 
treatment outcome (Shoham et al., 1990). An associa-
tion between a high serum LH concentration in the fol-
licular phase during gonadotrophin-releasing hormone 
(GnRH) pulsatile treatment and failure to conceive has 
been reported in PCOS patients (Jacobs & Homburg, 
1990). A retrospective analysis in normogonadotrophic 
anovulatory patients (n  =  154) suggested that the endog-
enous LH concentration prior to the start of ovulation 
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induction with gonadotrophin preparations containing 
only FSH activity does not affect the chances of achiev-
ing a pregnancy (Mulders et al., 2003a). A few studies 
have  measured  LH  concentrations  during  ovulation 
induction  with  FSH  preparations  (Coelingh  Bennink 
et al., 1998; Balasch et al., 2003), but the impact of 
endogenous LH concentrations during or at the end of 
gonadotrophin  stimulation  on  treatment  outcome  in 
PCOS patients has not been specifically addressed.
Due to the hypersecretion of LH in some patients 
with  PCOS,  gonadotrophin  preparations  containing 
only FSH activity were considered to have theoretical 
advantages  over  human  menopausal  gonadotrophin 
(hMG)  preparations  which  contain  both  FSH  and 
LH  activity  (Hillier,  1994;  Shoham,  2002;  Balasch, 
2004). However, the existing data do not support these 
theoretical concerns, and there have been no studies 
powered to detect differences in clinical outcome. The 
available individual studies and meta-analyses have not 
been able to document significant differences in ongo-
ing pregnancy and live birth rates between preparations 
containing  only  FSH  activity  and  hMG  preparations 
(Nugent et al., 2000; Platteau et al., 2006).
The major aim of the present retrospective study was 
to evaluate the roles of endogenous and exogenous LH 
activity on live birth rate in WHO group II anovula-
tory women stimulated with rFSH or highly purified 
menotrophins  (HP-hMG),  which  provide  FSH  and 
exogenous LH activity mainly in the form of human 
chorionic gonadotrophin (hCG). Thus, serum concen-
trations of LH represent mainly the endogenous LH 
activity in both groups, and serum hCG represents the 
exogenous LH activity, which is present only in the HP-
hMG group. Serum LH and hCG were compared be-
tween those women who achieved a live birth and those 
who did not, for both treatment regimens. To evaluate 
potential confounding predictors of live birth, we sub-
sequently performed a full logistic regression analysis of 
the associations between live birth rate and an extensive 
range of patient characteristics, as well as endocrino-
logical variables at baseline and end of stimulation.
Material and methods
Study population
This  retrospective  study  was  based  on  184  women 
with normogonadotropic anovulatory infertility (WHO 
Group II) who participated in a prospective randomised 
controlled multicentre trial, which had ovulation rate as 
the primary outcome measure after ovulation induction 
with  different  gonadotrophin  preparations  [HP-hMG 
(Menopur, Ferring Pharmaceuticals A/S, Copenhagen, 
Denmark) and rFSH (Gonal-F, Merck Sereno, Geneva, 
Switzerland)] using a low-dose step-up protocol (Plat-
teau et al., 2006). HP-hMG contributes both FSH and 
LH activity; the LH-activity being almost completely 
(>95% immunoreactivity) derived from hCG molecules 
(Wolfenson et al., 2005). As reported (Platteau et al., 
2006), the ovulation rates in response to stimulation 
with the two gonadotrophin preparations are similar: 
84.9% (79/93) for the rFSH group and 83.5% (76/91) 
for the HP-hMG group. In order to investigate the im-
pact of a number of baseline and treatment-associated 
variables on live birth rate per se (i.e. ruling out the no 
live birth response due to lack of ovulation), only the 
women who ovulated after stimulation were included in 
the study cohort (n  =  155). Main inclusion criteria were 
chronic anovulation (amenorrhoea, oligomenorrhea, or 
low  progesterone  concentrations  in  menstrual  cycles 
of duration of 21–35 days), failure to ovulate with CC 
doses of at least 100 mg/day for at least 5 days or failure 
to conceive after three cycles of ovulation induction with 
CC, an age of at least 18 but not more than 39 years, 
a body mass index (BMI) of 19–35 kg/m2, and early 
follicular serum FSH concentrations between 1 and 12 
IU/l. The study was carried out in accordance with the 
Declaration of Helsinki on good clinical practice, and 
ethical committee approval was obtained in all partici-
pating centres. Written informed consent was obtained 
from all trial subjects.
Study protocol
Stimulation  treatment  was  started  2–5  days  after  a 
spontaneous or progesterone-induced menstrual bleed. 
The starting dose of gonadotrophin was 75 IU daily, 
which was maintained for 7 days. After the first 7 days, 
the dose was either maintained or increased by 37.5 IU 
increments according to individual responses. All sub-
jects were maintained on their specific dose concentra-
tion for at least 7 days. The maximum permitted daily 
dose was 225 IU, and the women were treated with the 
gonadotrophin for a maximum of 6 weeks. A single dose 
of 5,000 IU of hCG (Profasi, Merck Serono, Geneva, 
Switzerland) was given to trigger ovulation when one 
follicle of ≥17 mm or two to three follicles of ≥15 mm 
were observed by vaginal ultrasound. Any medication 
for luteal support (e.g. progesterone or hCG) was pro-
hibited.
Blood samples were taken on stimulation day 1 (prior 
to the start dosing with gonadotrohins) and at the end 
of stimulation (at least 8 h after the last gonadotrophin 
dose). Serum was analysed for endocrine variables by a 
central laboratory using an electrochemiluminescence 
immunoassay (LH, FSH, hCG, testosterone, prolactin, 
sex  hormone-binding  globulin  (SHBG)),  a  radioim-
munoassay  (estradiol,  androstenedione),  a  chemolu-
minescence assay (insulin), and an enzymatic method 
(glucose).The  lower  detection  limits  of  the  validated 
analytical methods were as follows: LH 0.10 IU/l, FSH 
0.10 IU/l, hCG 0.10 IU/l, total testosterone 0.17 nmol/l, 
prolactin 0.3 μg/l, SHBG 2 nmol/l, estradiol 55 pmol/l, 
androstenedione 0.10 nmol/l, insulin 14.4 pmol/l and 
glucose 1.1 mmol/l.
Ovulation was defined as a serum progesterone con-
centration of ≥7.9 ng/ml (≥25 nmol/l) in the mid-luteal 
phase  (6–9  days  after  hCG).  Clinical  pregnancy  was 194  J.-C. Arce & J. Smitz
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defined as a transvaginal ultrasound showing at least 
one intrauterine gestation sac with foetal heart beat 7–9 
weeks after hCG administration. Live birth was defined 
as a cycle that resulted in at least one live born neonate, 
regardless of the number of other neonates (live born or 
still born).
Statistical analysis
Student’s t-test was used for comparison of continuous 
variables between those women who did, and those who 
did not, achieve a live birth. The demographic and pre-
stimulation variables as well as the variables obtained 
at end of ovarian stimulation for each treatment group 
were included in a primary univariate logistic regres-
sion  analysis  with  the  dependent  variable  live  birth. 
The predictive value of each variable was summarised 
as  an  odds  ratio  with  95%  confidence  interval. The 
hCG values were multiplied by 10 to have a more in-
terpretable OR estimate. All variables with a p-value 
<0.05 in the univariate regression analysis were then 
included in a secondary multivariate regression analysis 
for each treatment group. The multivariate model was 
reduced stepwise and the variables that were significant 
predictors of live birth at the <5% level are presented. 
Model fit was checked by the Hosmer and Lemeshow 
Goodness-of-Fit  test.  Tests  for  differences  between 
variables in subgroups stratified into the 25th and 75th 
percentiles of exogenous serum hCG concentrations at 
end of stimulation were performed using the Kruskal–
Wallis test for continuous data and the Chi-square test 
for categorical data.
Results
Table I shows the demographics and baseline character-
istics of the women who ovulated in response to stimu-
lation. All prestimulation variables were comparable in 
the two treatment groups.
Seventeen women in the rFSH group had a positive 
clinical pregnancy test and 16 of them achieved a live 
birth (14 singletons and 2 multiples). In the HP-hMG 
group, 14 women had a positive clinical pregnancy test 
and 13 of them achieved a live birth (all singletons). 
The endogenous LH concentrations prior to treatment 
did not differ significantly between the live birth and 
non-live birth subgroups in rFSH- or HP-hMG-treated 
women (Table II). Neither were the endogenous LH 
concentrations at end of stimulation significantly dif-
ferent  between  the  two  subgroups  of  each  treatment 
regimen. However, the mean exogenous serum concen-
tration of hCG at end of HP-hMG treatment was found 
to be 30% higher (p  =  0.010) in the subgroup of women 
who achieved a live birth compared with the non-live 
birth subgroup.
In the group of women who were stimulated with 
rFSH, the univariate logistic regression analysis of the 
associations  between  demographic  and  prestimula-
tion variables as well as the variables obtained at end 
Table I.  Demographics and baseline characteristics.
Variables rFSH (n  =  79) HP-hMG (n  =  76) All (n  =  155)
Female age (years) 29.4  ±  3.8 29.4  ±  4.0 29.4  ±  3.9
BMI (kg/m2) 25.2  ±  4.3 25.8  ±  5.1 25.5  ±  4.7
Waist-to-hip ratio 0.82  ±  0.09 0.83  ±  0.12 0.83  ±  0.10
Primary infertility (%) 65 55 60
Duration of infertility (years) 2.9  ±  1.9 2.9  ±  1.8 2.9  ±  1.9
Previous ovulation induction cycles 4.8  ±  2.5 4.7  ±  2.5 4.7  ±  2.5
Clomiphene citrate non-responders
  Failure to ovulate* (%) 38 53 45
  Failure to conceive† (%) 62 47 55
Mean ovarian volume (cm3) 8.2  ±  4.3 8.1  ±  4.1 8.1  ±  4.2
Antral follicle count 22  ±  14 23  ±  17 23  ±  16
LH (IU/l) 7.6  ±  4.5 7.2  ±  4.8 7.4  ±  4.6
LH > 10 IU/l (%) 23 22 23
FSH (IU/l) 5.4  ±  2.7 5.1  ±  1.3 5.2  ±  2.1
LH:FSH ratio 1.6  ±  1.2 1.5  ±  1.1 1.5  ±  1.1
Prolactin (μg/l) 12  ±  7 13  ±  15 12  ±  11
Androstenedione (nmol/l) 7.2  ±  3.5 8.0  ±  5.0 7.6  ±  4.3
Total testosterone (nmol/l) 1.6  ±  0.6 1.8  ±  0.7 1.7  ±  0.6
SHBG (nmol/l) 62  ±  43 57  ±  38 59  ±  40
Free androgen index 4.1  ±  3.3 4.9  ±  4.6 4.5  ±  4.0
Estradiol (pmol/l) 158  ±  63 156  ±  91 157  ±  77
Glucose (mmol/l) 5.1  ±  0.7 5.2  ±  0.7 5.1  ±  0.7
Insulin (pmol/l) 98  ±  101 109  ±  117 103  ±  109
Insulin:glucose ratio 2.8  ±  2.6 2.9  ±  2.7 2.8  ±  2.7
Variables expressed as mean  ±  SD, or %.
*At least 100 mg/day for at least 5 days.
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Table II.  Serum concentrations of LH at baseline, and of LH and hCG at end of gonadotrophin stimulation.
LH activity
rFSH HP-hMG
No live birth (n  =  63) Live birth (n  =  16) p No live birth (n  =  63) Live birth (n  =  13) p
Baseline
  Endogenous LH (IU/l) 7.56  ±  4.42 8.00  ±  4.93 0.454 6.97  ±  4.04 8.54  ±  7.63 0.287
End of stimulation
  Endogenous LH (IU/l) 14.5  ±  17.8* 9.41  ±  6.54 0.289 11.2  ±  9.91* 9.45  ±  9.11 0.666
  Exogenous hCG (IU/l) – – – 0.98  ±  0.35* 1.27  ±  0.39 0.010
The data are expressed as mean  ±  SD.
*57 women attended the end-of-stimulation visit.
Table III.  Univariate logistic regression analysis of the association between live birth and clinical, sonographic and endocrinological parameters 
prior to start of ovarian stimulation and at end of stimulation.
Variables
rFSH (n  =  79) HP-hMG (n  =  76)
OR 95% CI p-value OR 95% CI p-value
Baseline
  Female age (years) 0.89 0.76–1.04 0.139 0.94 0.80–1.09 0.395
  BMI (kg/m2) 1.07 0.94–1.21 0.318 0.96 0.85–1.08 0.508
  Waist-to-hip ratio 1.02 0.55–1.88 0.944 1.32 0.84–2.05 0.226
  Menstrual cycle 
pattern*
3.75 0.78–18.03 0.098 6.00 0.73–49.3 0.095
  Duration of 
infertility (years)
0.90 0.64–1.27 0.551 0.70 0.41–1.19 0.188
  Failure to ovulate 
on cc
0.54 0.18–1.63 0.271 0.65 0.19–2.19 0.482
  Failure to conceive 
on cc
1.86 0.62–5.65 0.271 1.55 0.46–5.26 0.482
  Antral follicle count 1.02 0.99–1.06 0.192 1.03 1.00–1.07 0.070
  Mean ovarian 
volume (cm3)
1.02 0.90–1.15 0.761 0.99 0.85–1.16 0.948
  LH (IU/l) 1.02 0.91–1.15 0.723 1.06 0.95–1.19 0.289
  LH (≤10 IU/l vs. 
>10 IU/l)
0.59 0.17–2.02 0.397 0.48 0.12–1.87 0.289
  FSH (IU/l) 0.58 0.38–0.90 0.015 1.08 0.69–1.70 0.733
  Estradiol (pmol/l) 1.00 0.99–1.01 0.993 0.99 0.97–1.00 0.041
  Prolactin (μg/l) 0.97 0.88–1.07 0.516 0.92 0.80–1.05 0.207
  Androstenedione 
(nmol/l)
1.07 0.92–1.25 0.357 0.94 0.80–1.10 0.443
  Total testosterone 
(nmol/l)
1.96 0.77–4.95 0.155 0.56 0.20–1.53 0.255
  SHBG (nmol/l) 1.00 0.99–1.01 0.863 1.01 0.99–1.02 0.481
  Free androgen index 1.14 0.98–1.33 0.090 0.86 0.69–1.09 0.208
  Glucose (mmol/l) 0.67 0.28–1.60 0.361 0.60 0.24–1.52 0.282
  Insulin (pmol/l) 1.00 1.00–1.01 0.811 0.99 0.98–1.00 0.205
  Insulin: glucose 
ratio
1.05 0.87–1.27 0.629 0.77 0.50–1.16 0.210
End of stimulation
  Follicular 
development (multiple 
vs. mono)
1.81 0.58–5.63 0.306 0.63 0.16–2.54 0.516
  Duration of 
gonadotrophin (days)
1.04 0.93–1.17 0.507 1.02 0.93–1.12 0.675
  Total dose of 
gonadotrophin (IU)
1.00 1.00–1.00 0.641 1.00 1.00–1.00 0.735
  Endometrial 
thickness (mm)
1.25 0.98–1.61 0.078 0.90 0.67–1.20 0.461
  Estradiol (pmol/l) 1.00 1.00–1.00 0.349 1.00 1.00–1.00 0.442
  FSH (IU/l) 0.80 0.59–1.08 0.147 1.18 0.87–1.61 0.282
  hCG (IU/l) – – – 1.25 1.04–1.50 0.015
  LH (IU/l) 0.97 0.92–1.02 0.273 0.98 0.91–1.05 0.568
  LH (≤10 IU/l vs. 
>10 IU/l)
0.87 0.28–2.67 0.807 1.01 0.29–3.47 0.993
OR, odds ratio; CI, confidence interval.
*Amenorrhea and oligomenorrhea vs. anovulatory cycles.196  J.-C. Arce & J. Smitz
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Figure  1.Live  birth  rate  according  to  the  ≤P25,  >P25–P75  and 
>P75 percentiles of serum hCG concentrations at end of HP-hMG 
stimulation. Seventy women attended the end-of-stimulation visit.
of ovarian stimulation and live birth showed that there 
was no significant association between the endogenous 
LH concentration and live birth rate; neither at base-
line [OR  =  1.02 (95% CI: 0.91–1.15), p  =  0.723] nor at 
end  of  stimulation  [OR  =  0.97  (95%  CI:  0.92–1.02), 
p  =  0.273)  (Table  III). The  only  variable  significantly 
associated with live birth rate in this treatment group 
was the serum concentration of FSH at baseline, which 
was negatively associated with live birth rate [OR  =  0.58 
(95% CI: 0.38–0.90), p  =  0.015]. The variables yielding 
a p-value ≤0.1 in the univariate tests entered into a mul-
tivariate logistic regression analysis. As in the univariate 
tests, only FSH at baseline was a significant predictor of 
live birth rate at the 5% level.
In the univariate logistic regression analysis of the 
group of women stimulated with HP-hMG, two vari-
ables were found to be significantly associated with the 
live birth rate; the serum concentrations of estradiol at 
start of stimulation [OR  =  0.99 (95% CI: 0.97–1.00), 
p  =  0.041] and exogenous hCG at end of stimulation 
[OR  =  1.25  (95%  CI:  1.04–1.50),  p  =  0.015].  Similar 
to the rFSH group, neither the endogenous LH con-
centration at start of stimulation [OR  =  1.06 (95% CI: 
0.95–1.19),  p  =  0.289]  nor  the  LH  concentration  at 
end of stimulation [OR  =  0.98 (95% CI: 0.91–1.05), 
p  =  0.568] was significantly associated with live birth 
rate. Furthermore, there was no correlation (p  =  0.340) 
between the concentrations of LH and hCG at end 
of stimulation in the group of women stimulated with 
HP-hMG (data not shown). There was a trend towards 
an association between live birth rate and antral fol-
licle count [OR  =  1.03 (95% CI: 1.00–1.07), p  =  0.070], 
while no other demographic, baseline, clinical, sono-
graphic  or  endocrine  variable  was  associated  with 
live birth rate. When eliminating the non-significant 
variables stepwise in a multivariate logistic regression 
analysis, the exogenous hCG concentration at the end 
of  stimulation  was  the  only  significant  predictor  of 
live birth rate at the 5% level in the HP-hMG group. 
Model fit was checked by the Hosmer and Lemeshow 
Goodness-of-Fit  test,  which  gave  an  acceptable  fit 
(p  =  0.518).
The HP-hMG treated women were stratified into the 
25th and 75th percentiles (P) of exogenous serum hCG 
concentrations at end of stimulation, resulting in sub-
groups of ≤P25, >P25–P75, and >P75. The live birth 
rate was lowest (6%) in the ≤P25 quartile and highest 
(35%) in the >P75 quartile (Figure 1). No significant 
differences between the percentile subgroups of hCG 
were observed regarding the demographic and baseline 
characteristics and the endocrine and sonographic vari-
ables at the start of stimulation, except for a significantly 
(p  =  0.028) higher antral follicle count in the >P25–P75 
percentile compared to the two extreme quartiles and a 
trend (p  =  0.099) towards higher BMI in those women 
with lower hCG concentrations. Concerning stimula-
tion  characteristics,  the  duration  of  stimulation,  the 
total dose of gonadotrophin and the dose on the last 
stimulation day as well as the levels of FSH and estra-
diol at end of stimulation were found to be highest in 
the >P75 quartile (Table IV).
Discussion
The present study did not find a significant association 
between serum concentrations of LH at baseline and live 
birth rate, neither in the rFSH group nor in the HP-hMG 
group. In line with this observation, the endogenous LH 
levels were similar in women who achieved a live birth 
and in those who did not. The lack of association be-
tween the LH level and outcome in the current study is 
in agreement with the results of a retrospective study in 
women with normogonadotropic anovulatory infertility 
resistant to CC-therapy treated with FSH activity go-
nadotrophin preparations (Mulders et al., 2003a), but 
in contrast to the meta-analysis of four studies in this 
patient category undergoing ovulation induction with 
FSH (Mulders et al., 2003b). The meta-analysis found 
a small, but significant, positive association between el-
evated basal LH levels and pregnancy rates. The present 
study, however, used a single sensitive LH assay applied 
to all study samples in a central laboratory, which may 
partly explain the different results.
The present study shows for the first time that in-
creased  serum  concentrations  of  exogenous  hCG  at 
the end of stimulation were associated with higher live 
birth rates in normogonadotropic anovulatory infertile 
women treated with HP-hMG. Actually, among all the 
variables obtained at baseline or end of stimulation, 
the hCG concentration was the only variable predic-
tive of treatment outcome in the multivariate logistic 
regression analysis. This is an interesting, novel find-
ing in a PCOS population with already normal or high 
endogenous  LH  concentrations  prior  to  starting  the 
ovulation induction treatment. In this context, it is im-
portant to note that any interpretation of the relation 
between endogenous LH concentrations and outcome 
in HP-hMG-treated women is confounded by the fact Exogenous hCG birth rate and live  197
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that  there  is  an  intervention  with  exogenous  hCG, 
supplementing additional LH activity.
The higher serum hCG concentrations (as well as 
FSH concentrations) in patients in the highest quartile 
group at the end of stimulation could be explained by 
their higher final daily dose of HP-hMG. These patients 
had a longer duration of stimulation in order to achieve 
the desired follicular response, but also had significantly 
higher  estradiol  levels  than  the  patients  in  the  other 
quartiles, despite an apparently comparable degree of 
follicular response. The finding of higher estradiol levels 
despite similar follicular response could reflect the effect 
of higher hCG levels on follicular differentiation. Also, 
the  number  of  antral  follicles  was  different  between 
the percentile subgroups, but was not higher for the 
>75th percentile. A trend towards a lower BMI in the 
highest quartile group is in line with a previous report 
(Chan et al., 2003), which showed an inverse associa-
tion between BMI and bioavailability of hCG. Despite 
all these observations, the concentration of hCG at the 
end of HP-hMG stimulation was identified as the sole 
significant positive predictor of live birth rate, while de-
mographic variables, including BMI, or other variables 
at baseline or at end of stimulation did not add further 
to the prediction.
The interpretation of this investigation is influenced 
by certain methodological aspects of the hormone mea-
surements. Immunoassay determination of LH concen-
trations based on blood sampling every 15 minutes leads 
to documented major oscillations within short intervals, 
which are attributed to the pulsatile release of LH and 
potentially to the exogenous pharmacological interven-
tions  (Griesinger  &  Diedrich,  2006).  In  the  present 
study, the analysis of endogenous LH concentrations 
at baseline and the end of stimulation was based on a 
single blood sample on each occasion which may not 
truly reflect the mean daily endogenous LH concentra-
tion or the overall exposure of reproductive tissues to 
Table IV.  Demographics, baseline and stimulation characteristics by hCG concentration at end of HP-hMG stimulation.
 
 
Variables
hCG (IU/l)
 
 
p-value*
≤P25 >P25–P75 >P75
n  =  18 n  =  35 n  =  17
Baseline
  Female age (years) 30.1  ±  3.6 29.3  ±  3.9 28.6  ±  4.7 0.561
  BMI (kg/m2) 27.8  ±  4.1 26.0  ±  5.5 24.3  ±  5.3 0.099
  Waist-to-hip ratio 0.83  ±  0.06 0.83  ±  0.12 0.86  ±  0.17 0.759
  Duration of infertility (years) 3.0  ±  1.5 2.7  ±  2.1 2.7  ±  1.3 0.432
  Primary infertility 39% 61% 53% 0.251
  Antral follicle count 17  ±  11 27  ±  15 21  ±  24 0.028
  Mean ovarian volume (cm3) 8.2  ±  3.5 8.4  ±  4.2 7.3  ±  4.5 0.468
  LH (IU/l) 5.3  ±  2.0 6.9  ±  4.0 9.1  ±  7.4 0.452
  FSH (IU/l) 5.4  ±  1.4 4.7  ±  1.3 5.4  ±  1.3 0.174
  Estradiol (pmol/l) 132  ±  40 176  ±  114 151  ±  78 0.237
  Progesterone (nmol/l) 3.1  ±  1.3 4.7  ±  10.0 2.9  ±  2.3 0.545
  Prolactin (μg/l) 16.6  ±  27.3 11.9  ±  6.6 10.5  ±  6.3 0.533
  Androstenedione (nmol/l) 7.7  ±  3.7 7.9  ±  4.7 9.2  ±  7.2 0.974
  Total testosterone (nmol/l) 1.7  ±  0.5 1.8  ±  0.6 1.8  ±  1.0 0.583
  SHBG (nmol/l) 43.3  ±  25.8 60.2  ±  38.1 61.5  ±  47.0 0.200
  Glucose (mmol/l) 5.3  ±  0.7 5.2  ±  0.8 5.0  ±  0.6 0.714
  Insulin (pmol/l) 135  ±  132 120  ±  136 74  ±  57 0.099
  Insulin:glucose ratio 3.6  ±  3.0 3.2  ±  3.2 2.1  ±  1.5 0.133
End of stimulation
  Subjects with monofollicular 
development (%)
67 69 59 0.466
  Number of follicles ≥12 mm 2  ±  1 2  ±  2 2  ±  2 0.780
  Duration of gonadotrophin 
(days)
9.9  ±  2.6 13.6  ±  5.3 19.9  ±  7.7 <0.001
  Total dose of gonadotrophin 
(IU)
746  ±  198 1225  ±  669 2014  ±  1102 <0.001
  Last gonadotrophin dose (IU) 75  ±  0 97.5  ±  27.6 121.3  ±  33.9 <0.001
  Endometrial thickness (mm) 9.6  ±  1.8 9.5  ±  2.2 9.5  ±  2.6 0.964
  Estradiol (pmol/l) 831  ±  247 1455  ±  1524 1644  ±  1552 0.017
  FSH (IU/l) 8.4  ±  2.5 9.1  ±  1.2 11.6  ±  0.90 <0.001
  hCG (IU/l) 0.6  ±  0.1 1.0  ±  0.2 1.5  ±  0.2 <0.001
  LH (IU/l) 14.8  ±  10.9 8.8  ±  6.6 10.9  ±  12.6 0.053
  Subjects with LH > 10 IU/l (%) 56 29 41 0.156
Variables expressed as mean  ±  SD, or %.
*Kruskal–Wallis test for continuous and chi-square test for categorical data.198  J.-C. Arce & J. Smitz
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LH. Furthermore, the biological activity of the LH and 
hCG concentrations may not readily be extrapolated 
from the results of an immunoassay. Given the longer 
terminal half-life of hCG, the bioactivity contribution 
in vivo of hCG may be greater than could actually be 
extrapolated  from  immunoassay  concentrations  (de 
Leeuw et al., 1996).
 As WHO type II anovulatory patients generally have 
normal or elevated LH concentrations, supplementation 
of LH activity is not considered to be required in this pa-
tient category. However, the finding in the present study 
that the live birth rate in the >75th percentile of hCG 
in HP-hMG stimulated women was 35% compared to 
20% in the rFSH group may suggest that exogenous 
hCG  exerts  effects  other  than  pure  LH  substitution. 
To date, no clinical studies have been adequately de-
signed to investigate the effect of LH supplementation 
on live birth rates in anovulatory infertility WHO type 
II patients. Most of the data on potential favourable ef-
fects of LH activity on oocyte/embryo quality and on 
the endometrium are based on superovulating patients 
undergoing in vitro fertilisation/intracytoplasmic sperm 
injection  (IVF/ICSI)  cycles  or  oocyte  donors,  which 
usually exclude patients with PCOS (Acevedo et al., 
2004; Platteau et al., 2004; Lisi et al., 2005; Smitz et al., 
2007; ziebe et al., 2007; Weghofer et al., 2008; Hud-
dleston et al., 2009).
In  summary,  in  anovulatory  patients  with  normal 
or  elevated  baseline  endogenous  LH  concentrations 
undergoing ovulation induction with gonadotrophins, 
the LH concentration at baseline or end of stimulation 
is not significantly associated with live birth rate. The 
exogenous  LH  activity,  provided  mainly  in  the  form 
of hCG by using the HP-hMG gonadotrophin prepa-
ration, does not appear to be detrimental to live birth 
rates. Patients with higher serum hCG levels at the end 
of stimulation actually had the higher live birth rates in 
this treatment regimen.
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